CytomX Therapeutics, Inc. (CTMX) Net margin 2016–2025
CytomX Therapeutics, Inc. (CTMX) net profit margin by fiscal year — reported net income divided by reported revenue.
-22.8%FY2025 · since FY2016: -458.5% → -22.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -22.8% | -45.9 pp |
| FY2024 | 23.1% | +23.6 pp |
| FY2023 | -0.6% | +186.3 pp |
| FY2022 | -186.8% | +123.7 pp |
| FY2021 | -310.5% | -215.8 pp |
| FY2020 | -94.7% | +399.0 pp |
| FY2019 | -493.7% | -351.5 pp |
| FY2018 | -142.2% | -82.0 pp |
| FY2017 | -60.2% | +398.4 pp |
| FY2016 | -458.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTMX financial trends
CTMX RevenueCTMX Net incomeCTMX Gross profitCTMX Gross marginCTMX Operating incomeCTMX Operating marginCTMX Operating cash flowCTMX Free cash flowCTMX Capital expendituresCTMX Return on equityCTMX Stock buybacksCTMX Dividends paidCTMX Total assetsCTMX Total liabilitiesCTMX Shareholders’ equityCTMX overview →